Chairman of the Board and former Chief Executive Officer · Q32 Bio Inc. (QTTB)

Arthur Tzianabos

A named executive officer of Q32 Bio in every fiscal year CompBrief holds from FY2017 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,672,061

Salary $437,151Stock awards $157,180

FY2021: $3,607,339

1st of 4 named executive officers at Q32 Bio by FY2022 total.

4 named officers on file for Q32 Bio, FY2022

Arthur Tzianabos’s pay file — $29

  • 6 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Q32 Bio’s whole pay program stands against its peers

  • Q32 Bio’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on QTTB→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Arthur Tzianabos’s full pay file as a PDF — free

More than this page: up to 10 years of Arthur’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Arthur Tzianabos compensation by year

Q32 Bio Summary Compensation Table · all 6 fiscal years held
In US dollars, as Q32 Bio reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021FY2022
Salary$422,300$490,500$537,600$563,200$583,100$437,151
Bonus$0$0$0$0$0$0
Stock awards$0$0$0$0$578,760$157,180
Option awards$1,815,320$3,562,722$4,217,097$0$2,116,074$603,575
Non-equity incentive$168,920$250,000$295,680$309,760$320,705$362,100
Pension and deferred compensation$0$0$0$0$0$0
All other$0$9,893$12,500$13,000$8,700$112,055
Total$2,406,540$4,313,115$5,062,877$885,960$3,607,339$1,672,061

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Q32 Bio Inc. DEF 14A filed April 28, 2023, accession 0000950170-23-015750, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Q32 Bio Inc. filed document, accession 0000950170-23-015750. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

$2.4M
$4.3M
$5.1M
$886K
$3.6M
$1.7M
FY17
FY18
FY19
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU58,000$73,080—
RSU28,140$35,456—
Option4,230—$24.28
Option96,959—$19.92
Option269,792—$2.71
Option132,292—$13.78

Per the Outstanding Equity Awards at Fiscal Year-End table in Q32 Bio Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

16 Form 4 lines since the FY2022 proxy (filed April 28, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-12Grant or award derivative—10,826$0.0010,826
2026-06-12Grant or award derivative—9,810$0.009,810
2025-10-23Grant or award derivative—53,521$0.0053,521
2025-02-24Grant or award derivative—12,767$0.0012,767
2025-02-24Grant or award derivative—25,674$0.0025,674
2025-02-24Disposition to the issuer derivative—12,767$0.000
2025-02-24Disposition to the issuer derivative—25,674$0.000
2024-03-25Grant or award derivative—12,767$0.0012,767

The 8 most recent of 16 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Q32 Bio’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Arthur Tzianabos · this pageChairman of the Board and former Chief Executive Officer$1,672,061
Albert SeymourChief Executive Officer$1,197,487
W. Bradford SmithChief Financial and Business Officer and Treasurer$994,251
Paul AllowayChief Legal Officer and Secretary$868,639

Board service

Q32 Bio board · FY2024–FY2025
Director compensation in US dollars, as Q32 Bio reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$45,000—$118,237—$163,237
FY2024$51,427—$164,607—$216,034

Each year as the company reported it in Q32 Bio's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Q32 Bio pays directors a $40,000 cash retainer and $114,000 in Options. As stated in Q32 Bio's FY2025 proxy.

Committees

Research and Development

The full Q32 Bio compensation record

free company brief

This page is one person within Q32 Bio's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Q32 Bio's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Arthur Tzianabos's compensation dossier · One-time report. No refunds.